



**ASX ANNOUNCEMENT
& MEDIA RELEASE**

18 October 2007

RESOLUTIONS PASSED AT ANNUAL GENERAL MEETING

At the Annual General Meeting of Biomedical company, **Tissue Therapies Limited (ASX: TIS)** held on 18 October 2007 the following resolutions were passed by a show of hands:

2. Directors' Remuneration Report

'That the section of the Directors' Report dealing with the remuneration of the Company's Directors, Company Secretary and Senior Executives ('Remuneration Report') be adopted.'

3. Re-election of Roger Clarke

'That Roger Clarke, who retires by rotation in accordance with Listing Rule 14.4 and Rule 16.1 of the Company's Constitution, and being eligible and having offered himself for re-election, be re-elected as a Director of the Company.'

4. Re-election of Donald Home

'That Donald Home who retires in accordance with Listing Rule 14.4 and Rule 13.2 of the Company's Constitution, and being eligible, be re-elected as a Director of the Company.'

5. Ratification and Approval of Previous Allotment and Issue of Shares

'That for the purposes of Listing Rule 7.4 and for all other purposes, the prior issue and allotment of 4,040,000 shares at an issue price of \$0.50 under a share placement made on 26 July 2007 be ratified.'

6. Approval of Equity Option Plan

'That, for the purpose of Listing Rule 7.2, exception 9(b) and for all other purposes, the Company approve the issue of securities under the Equity Option Plan of the Company, the terms and conditions of which are summarised in the Explanatory Memorandum accompanying this Notice of Meeting.'

7. Issue of Options to Directors

That, pursuant to section 208(1)(a) of the Corporations Act and Listing Rule 10.14, and in accordance with the Company's Equity Option Plan, the members of the Company approve the granting of options as follows, in the manner outlined in the Explanatory Memorandum:

- (a) *400,000 options to Dr Steven Mercer, Executive Director and Chief executive Officer; and*
- (b) *100,000 options to Donald Home, Director;*

Summary of Proxy Votes Lodged

Resolution Name	For	At Discretion of Proxy Holder	Against	Abstain
2	8,473,530	537,252	21,002	65,046
3	8,334,198	144,379	17,818	2,130
4	8,605,373	475,184	14,143	2,130
5	4,725,596	314,756	22,948	1,509,310
6	8,223,114	65,000	56,318	77,810
7(a)	8,219,515	392,709	48,463	86,764
7(b)	8,205,372	392,709	62,606	86,764

ENDS

Further information or for an interview:

Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: (07) 3839 9938

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a platform technology developed by tissue engineering experts at Queensland University of Technology for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration and cell culture.

Based on its VitroGro® platform technology, Tissue Therapies is developing more effective medical treatments for wounds and burns, integration of orthopaedic and medical implants, and other applications such as cosmeceuticals.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com